NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Update

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 322,800 shares, a decrease of 51.3% from the September 15th total of 663,000 shares. Based on an average daily volume of 1,060,000 shares, the short-interest ratio is currently 0.3 days. Currently, 2.4% of the company’s stock are sold short.

Separately, LADENBURG THALM/SH SH initiated coverage on NovaBay Pharmaceuticals in a research report on Wednesday, September 18th. They set a “buy” rating and a $1.10 price target on the stock.

Shares of NBY traded up $0.02 during trading hours on Monday, reaching $0.56. 146,100 shares of the company traded hands, compared to its average volume of 1,153,636. NovaBay Pharmaceuticals has a 12-month low of $0.23 and a 12-month high of $4.04. The business has a fifty day moving average price of $0.68 and a 200-day moving average price of $1.02.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter. The firm had revenue of $1.79 million for the quarter.

An institutional investor recently bought a new position in NovaBay Pharmaceuticals stock. Jane Street Group LLC purchased a new stake in NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 37,287 shares of the biopharmaceutical company’s stock, valued at approximately $63,000. Jane Street Group LLC owned about 0.18% of NovaBay Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

See Also: Market Timing

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.